ERBB2 and breast carcinoma: However, since cMLC-1 levels are higher in both HER2- (p<0.0001) and HER2+ patients (p=0.0549) compared to normal donors, although the latter difference did not reach a statistically significant level with the given small sample size, we anticipate that a larger sample size would result in a narrower 95% confidence interval for sensitivity and specificity to predict breast cancer, regardless of HER2 status.